prikaz prve stranice dokumenta Pristup kod pacijenta s poremećajem krvarenja u dentalnoj medicini
  Download
PDF 489.91 KB
master's thesis
Pristup kod pacijenta s poremećajem krvarenja u dentalnoj medicini
Zagreb: University of Zagreb, School of Dental Medicine, 2022. urn:nbn:hr:127:524611
Petrić, Karmen
University of Zagreb
School of Dental Medicine
Department of Oral Surgery

Institutional repository: University of Zagreb School of Dental Medicine Repository

Cite this document

Petrić, K. (2022). Pristup kod pacijenta s poremećajem krvarenja u dentalnoj medicini (Master's thesis). Zagreb: University of Zagreb, School of Dental Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:127:524611

Petrić, Karmen. "Pristup kod pacijenta s poremećajem krvarenja u dentalnoj medicini." Master's thesis, University of Zagreb, School of Dental Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:127:524611

Petrić, Karmen. "Pristup kod pacijenta s poremećajem krvarenja u dentalnoj medicini." Master's thesis, University of Zagreb, School of Dental Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:127:524611

Petrić, K. (2022). 'Pristup kod pacijenta s poremećajem krvarenja u dentalnoj medicini', Master's thesis, University of Zagreb, School of Dental Medicine, accessed 26 November 2024, https://urn.nsk.hr/urn:nbn:hr:127:524611

Petrić K. Pristup kod pacijenta s poremećajem krvarenja u dentalnoj medicini [Master's thesis]. Zagreb: University of Zagreb, School of Dental Medicine; 2022 [cited 2024 November 26] Available at: https://urn.nsk.hr/urn:nbn:hr:127:524611

K. Petrić, "Pristup kod pacijenta s poremećajem krvarenja u dentalnoj medicini", Master's thesis, University of Zagreb, School of Dental Medicine, Zagreb, 2022. Available at: https://urn.nsk.hr/urn:nbn:hr:127:524611

Metadata
TitlePristup kod pacijenta s poremećajem krvarenja u dentalnoj medicini
Title (english)Treatment approach in a patient with bleeding disorder in dental medicine
AuthorKarmen Petrić
MentorMarko Granić (mentor)
Committee memberMarko Granić (predsjednik povjerenstva)
Committee memberTomislav Škrinjarić (član povjerenstva)
Committee memberTomislav Katanec (član povjerenstva)
GranterUniversity of Zagreb
School of Dental Medicine
(Department of Oral Surgery)
Zagreb
Defense date and country2022-06-27, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Dental Medicine
Abstract
Sve veći broj pacijenta koji se liječe u ordinaciji dentalne medicine svakodnevno uzima antikoagulacijsku ili antiagregacijsku terapiju. Ovi lijekovi se propisuju kod kardiovaskularnih bolesti te ti pacijenti spadaju u rizičnu skupinu za razne stomatološke zahvate. Antikoagulacijski lijekovi koje koristi najveći dio pacijenata su varfarinska skupina i novi antikoagulacijski lijekovi (NOAK), koje čine dabigatran, apiksaban i rivaroksaban. Varfarin inhibira sintezu faktora zgrušavanja koji su ovisni o djelovanju vitamina K. Dabigatran inhibira trombin, dok apiksaban i rivaroksaban inhibiraju faktor Xa. U antiagregacijskoj terapiji najkorišteniji su acetilsalicilna kiselina, koja inhibira sintezu tromboksana A2, i k lopidogrel, koji inhibira agregaciju trombocita preko posrednika adenozin difosfata. Antikoagulacijski i antiagregacijski lijekovi, osim što sprječavaju tromboembolijske događaje, produljuju vrijeme krvarenja. Pacijenti na takvoj terapiji svakodnevno se susreću u ordinaciji dentalne medicine te je njihovom liječenju, posebice zahvatima kod kojih dolazi do pojačanog krvarenja, potrebno pristupiti s oprezom zbog mogućih komplikacija produljenog postoperativnog krvarenja.
Abstract (english)
More and more patients treated in dental offices are taking daily anticoagulant or antiplat elet therapy. These drugs are prescribed for cardiovascular diseases, and these patients belong to the risk group for various dental procedures. The anticoagulants taken by most patients belong to the warfarin group and the new anticoagulants (NOAC), which include dabigatran, apixaban, and rivaroxaban. Warfarin inhibits the synthesis of clotting factors that are dependent on the action of vitamin K. Dabigatran inhibits thrombin, while apixaban and rivaroxaban inhibit factor Xa. For antiplatelet therapy, acetylsalicylic acid, which inhibits thromboxane A2 synthesis, and clopidogrel, which inhibits platelet aggregation via adenosine diphosphate mediators, are the most commonly used drugs. Anticoagulant and antiplatelet drugs not only prevent thromboembolic events but also prolong bleeding time. Patients receiving such therapy are encountered daily in dental practice, and caution should be exercised in their treatment, especially during procedures involving increased bleeding, because of possible complications from prolonged postoperative bleeding.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:127:524611
Study programmeTitle: dental medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica dentalne medicine (doktor/doktorica dentalne medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2022-10-19 12:31:07